Portland, OR, April 13, 2021 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, “Cell Therapy Market by Cell Type (Stem Cell and Non-Stem Cell), Therapy Type (Autologous and Allogenic), Therapeutic Area (Malignancies, Musculoskeletal Disorders, Autoimmune Disorders, Dermatology, and Others), and End User (Hospitals & Clinics and Academic & Research Institutes): Global Opportunity Analysis and Industry Forecast, 2020–2027.” According to the report, the global cell therapy industry was estimated at $7.75 Billion in 2019, and is expected to hit $48.11 billion by 2027, registering a CAGR of 25.6% from 2020 to 2027.
Download Detailed COVID-19 Impact Sample Report at: https://www.alliedmarketresearch.com/request-for-customization/5330?reqfor=covid
Drivers, restraints, and opportunities-
Technological advancements in the medical field, rise in number of cell therapies in clinical studies, and increase in adoption of regenerative medicines fuel the growth of the market for global cell therapy. On the other hand, high costs of the therapy impede the growth to some extent. However, high growth potential in emerging markets is expected to pave the way for numerous opportunities for the key players in the sector.
Covid-19 scenario-
- Covid-19 has made biopharmaceutical reformers across the world come forward in regards to the human response to the pandemic which, in turn, has impacted the global cell therapy market positively. Also, several biotech organizations have started taking the very initiative to examine the virus’s genome so that they can come up with a sustainable vaccine.
- At the same time, the use of cell therapy has become quite predominant in the development of several regenerative medicines.
- Nonetheless, during the first phase of the lockdown, most clinics across the globe stopped undertaking new cases of stem cell therapy, organ transplants, and other treatments for the next few months which, in turn, hindered the market growth to some extent.
The stem cell segment to lead the trail by 2027-
Based on cell type, the stem cell segment contributed to nearly three-fifths of the global cell therapy market share in 2019 and is expected to retain its dominance by 2027. The same segment would also grow at the fastest CAGR of 26.1% throughout the forecast period. Increase in awareness regarding storage of stem cells have a positive effect on the market. Also, the number of stem cell banks is increasing in the developing nations. These factors fuel the growth of the segment.
For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/5330
The allogeneic segment to maintain the lion’s share-
Based on therapy type, the allogeneic segment accounted nearly three-fifths of the global cell therapy market revenue in 2019 and is anticipated to lead the trail from 2020 to 2027. Prevalence in cases of cancer relapse propels the segment growth. The autologous segment, on the other hand, would register the fastest CAGR of 26.0% by the end of 2027. Rise in incidences of chronic diseases such as autoimmune diseases, cancer, and blood disorders drives the segment growth.
North America to dominate in terms of revenue-
Based on region, North America generated the highest share in 2019, holding around half of the global cell therapy market. Huge amount of funding by governments and private firms for clinical trials boosts the market growth in the province. Simultaneously, Asia-Pacific would manifest the fastest CAGR of 31.6% from 2020 to 2027. Presence of large untapped opportunities such as expanding healthcare budgets and increase in disposable income of people in the region drive the market growth.
Key players in the industry-
- Osiris Therapeutics, Inc.
- Stemedica Cell Technologies, Inc.
- JCR Pharmaceuticals Co. Ltd.
- NuVasive, Inc.
- Cells for cells
- Kolon Tissue Gene, Inc.
- Medipost Co., Ltd.
- HolostemTerapieAvanzateS.r.l.
- Mesoblast Ltd.
Avenue Basic Plan | Library Access | 1 Year Subscription |
Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at $699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan.
Avenue Library Subscription | Request for 14 days free trial of before buying: https://www.alliedmarketresearch.com/avenue/trial/starter
Get more information: https://www.alliedmarketresearch.com/library-access
Similar Reports:
Stem Cell Umbilical Cord Blood Market - Global Opportunity Analysis and Industry Forecast, 2020–2027
3D Cell Culture Market - Global Opportunity Analysis and Industry Forecast, 2019-2027
Cell-based Assay Market - Global Opportunity Analysis and Industry Forecast, 2019-2027
Engineered T Cells Market - Global Opportunity Analysis and Industry Forecast, 2019–2027
Stem Cell Banking Market - Global Opportunity Analysis and Industry Forecast, 2019–2027
Cell Separation Technologies Market - Global Opportunity Analysis and Industry Forecast, 2019–2027
Cell Surface Marker Market - Global Opportunity Analysis and Industry Forecast, 2019–2027
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.